A detailed history of Jane Street Group, LLC transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Jane Street Group, LLC holds 177,260 shares of CNTA stock, worth $3.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
177,260
Holding current value
$3.11 Million
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.58 - $16.99 $1.52 Million - $3.01 Million
177,260 New
177,260 $2.83 Million
Q1 2023

May 15, 2023

BUY
$3.03 - $4.0 $43,186 - $57,012
14,253 Added 54.85%
40,238 $154,000
Q4 2022

Feb 14, 2023

SELL
$3.05 - $4.19 $11,974 - $16,449
-3,926 Reduced 13.13%
25,985 $80,000
Q3 2022

Nov 14, 2022

SELL
$3.8 - $5.91 $35,811 - $55,695
-9,424 Reduced 23.96%
29,911 $120,000
Q2 2022

Aug 16, 2022

BUY
$3.18 - $9.85 $125,085 - $387,449
39,335 New
39,335 $192,000

Others Institutions Holding CNTA

About Centessa Pharmaceuticals plc


  • Ticker CNTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,339,296
  • Market Cap $1.65B
  • Description
  • Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...
More about CNTA
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.